ClinicalTrials.gg
RecruitingNCT05913089Updated Jun 29, 2023

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

A Phase 2 interventional study of TQB2450 injection + Chemotherapy and TQB2450 injection + Anlotinib Hydrochloride Capsule in Non Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 10 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 9 under way, 2 of them phase 3. benmelstobart · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
13th of 14
58 · median 154
Started
2023
with 3 others
Phase 2
7 of 14
6 open now
Registered
7th of 14
by date
Lead sponsor
7 of 14
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by planned enrollment, is one of 4 that started in 2023, is one of 7 in phase 2, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting 4 weeks after surgery.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with stage II-IIIB (T3N2M0 only) Non-Small Cell Lung Carcinoma (NSCLC) and determined to be eligible for curable R0 excision, after pathologic diagnosis of puncture specimens;
  • ≥18 years old (calculated on the date of signing the ); Both men and women; (ECOG) score 0\~1; Predicted survival ≥3 months;
  • Have at least 1 according to (RECIST) 1.1 criteria within 28 days prior to initiation of treatment;
  • Has not received systemic antitumor therapy, including radiotherapy, chemotherapy and immunotherapy;
  • Agree to provide fresh or 6 month tumor tissue for programmed death ligand -1 () testing.
  • Major organs are functioning well.
  • Women of reproductive age should agree that they must use effective during the study period and for 6 months after the study, and that a negative serum or urine pregnancy test occurred within 7 days prior to study enrollment; Men should agree that effective contraception must be used during the study period and for 6 months after the study period ends.
  • The subjects voluntarily joined the study and signed the informed consent with good compliance.

Exclusion criteria

Exclusion Criteria:

  • Present or complication with other within 5 years.
  • Subjects are known to have genetic abnormalities with approved targeted drug therapy.
  • Cirrhosis, active hepatitis;
  • Cardio-cerebrovascular abnormalities;
  • Subjects with severe active infection within 4 weeks prior to initiation of study treatment; Or unexplained fever >38.0 ℃ occurred during screening and before first administration;
  • Patients with active tuberculosis within 1 year prior to enrollment;
  • Immunodeficiency disease;
  • History of active disease or autoimmune disease;
  • Preparing for or having previously received an organ transplant, or having received a hematopoietic stem cell transplant within 60 days prior to initial medication, or having a significant host transplant response;
  • Patients who required , systemic, or absorbable topical hormone therapy for immunosuppressive purposes and continued use within two weeks prior to randomization
  • Severe infection of grade 4 or higher occurred within 1 year prior to initiation of study therapy;
  • Severe lung disease;
  • History of pituitary or adrenal dysfunction;
  • History of severe mental disorder;
  • History of drug abuse, alcoholism or drug use;
  • Participated in clinical trials of other drugs within 30 days;
  • History of vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;
  • Received Chinese patent drugs with anti-tumor indications specified in the National Medical Product Administration approved drug package inserts within 2 weeks prior to initiation of administration
  • Had major surgery within 4 weeks prior to initiation of medication;
  • Other severe, acute, or chronic medical conditions or laboratory abnormalities that, in the investigator's opinion, may increase the risks associated with study participation or may interfere with the interpretation of the study results, or are otherwise unsuitable for participation in the clinical study;
  • The compliance of patients to participate in this clinical study is estimated to be insufficient.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    TQB2450 injection + Chemotherapy

    TQB2450 injection combined with chemotherapy, 21 days as a treatment cycle.

    Drug: TQB2450 injection + Chemotherapy

  • Experimental
    TQB2450 injection + Anlotinib Hydrochloride Capsule

    TQB2450 injection combined with anlotinib hydrochloride capsule, 21 days as a treatment cycle.

    Drug: TQB2450 injection + Anlotinib Hydrochloride Capsule

Interventions

  • DrugTQB2450 injection + Chemotherapy

    Drug page: Benmelstobart

    TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Chemotherapy is a systematic treatment that kill fast growing cells.

  • DrugTQB2450 injection + Anlotinib Hydrochloride Capsule

    Drug pages: Benmelstobart · Catequentinib hydrochloride

    TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1). Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

06

What researchers measure

Primary outcomes

  1. Major pathologic response (MPR)

    MPR defined as the percentage of subjects with a residual surviving tumor less than or equal to 10% after surgery.

    Time frame: Baseline up to 60 months.

Secondary outcomes

  1. Overall survival (OS)

    From randomization to the time of death from any cause.

    Time frame: Baseline up to 60 months.

  2. 2/3 year OS rate

    The ratio of two-year survival to three-year survival.

    Time frame: Baseline up to 36 months.

  3. Event free survival (EFS) assessed by the investigator.

    From the time of randomization to the occurrence of a predetermined event, including death, disease progression, change to chemotherapy, change to chemotherapy, addition of other treatments, occurrence of fatal or intolerable side effects, etc.

    Time frame: Baseline up to 60 months.

  4. Disease free survival (DFS) assessed by Blinded Independent Central Review (BICR)

    The time from randomization to the onset of tumor recurrence or death from any cause.

    Time frame: Baseline up to 60 months.

  5. Pathological complete response (pCR)

    Ratio of patients with no residual cancer cells found in the pathological examination after treatment.

    Time frame: Baseline up to 4 months.

  6. R0 resection rate

    The proportion of subjects who could undergo R0 resection, which is one of the surgery-related end points.

    Time frame: Baseline up to 4 months.

  7. Surgical delay rate

    The proportion of subjects who could not undergo surgery in time after neoadjuvant therapy.

    Time frame: Baseline up to 4 months.

  8. Pathological downgrading rate

    The proportion of patients with reduced lung cancer stage determined by pathological results after surgery.

    Time frame: Baseline up to 4 months.

07

Study locations

7 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jun 22, 2023
StartActual
Jun 14, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05913089
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Jun 14, 2023
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 29, 2023

Study contacts

Shugeng Gao, Doctor
Contact
13901362568@139.com
+86 13901362568

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Catequentinib hydrochloride

Start the discussion